OTCPicks.com

FEATURED COMPANY

FREEDOM ENVIRONMENTAL SERVICES INCORPORATED (OTC: FESI)
"Up 5.77% in morning trading"

Detailed Quote: www.otcpicks.com/quotes/FESI.php

Company Profile:
http://www.otcpicks.com/freedom-environmental-services.htm

Freedom Environmental Services, Inc. is an operating wastewater services company servicing commercial, institutional and municipal infrastructure customers and wastewater system protection programs. The company is developing and managing high yield liquid waste to Biodiesel and nutrients conversion programs driven by strategic acquisitions and its commercial customer base. Visit www.freedomservicesflorida.com for more information.

FESI News:

November 3 - DUNKIN' DONUTS® Franchisees Select Freedom Environmental Services, Inc. as Preferred Grease Collection Vendor

Michael Borish, Chairman and Chief Executive Officer of Freedom Environmental Services, Inc. (OTC: FESI) announced the execution of a contract with DUNKIN’ DONUTST™ franchisees that provides for the company to collect and dispose of grease from multiple franchise sites. The grease is integral to the company’s biofuel production strategy.

Mr. Borish noted that, “We are pleased that DUNKIN’ DONUTS franchisees have the confidence to select Freedom as vendor of choice to safely dispose of their waste products. This contract, along with the recently announced agreement with McDonald’s™ Corporation franchisees, provides the significant grease feedstock inventory necessary for the company’s stated annualized goal of producing 20 to 30 million gallons of Biodiesel by 2009.”

FEATURED COMPANY

BRITE-STRIKE TECHNOLOGIES INCORPORATED (OTC: BSTI)
"Up 16.67% in morning trading"

Detailed Quote: www.otcpicks.com/quotes/BSTI.php

Company Profile: http://www.otcpicks.com/brite-strike/brite-strike.htm

Brite-Strike Tactical Illumination Products, Inc. was started by two police officers to create world-class tactical LED flashlights that had the features that police officers and citizens need to keep them safe. Brite-Strike makes a promise to always use the latest technology, world-class components, highest design and manufacturing standards, so consumers can rely on Brite-Strike products when they are needed.

BSTI News:

October 6 - Brite-Strike Tactical Illumination Products, Inc. Receives Solar Product Patent

Brite-Strike Tactical Illumination Products, Inc. (OTC: BSTI) announced that it and Glenn Bushee, President of the Company, were awarded US Patent No. 7,350,692, for a Solar Powered Mailbox/Driveway Lamp. The product, the first commercial product the company has developed which utilizes LED lighting powered exclusively by small solar panels, will be introduced in 2009. The Company plans on developing and distributing products which have the potential to revolutionize the use of LED lighting in this country, through a wholly owned division, Brite-Strike Technologies.

"This product will be our first entry that marries the energy efficiency of LED light with the portability of solar," said Glenn Bushee, President of Brite-Strike. "The technology we developed for our revolutionary tactical flashlights has direct applications for many lighting applications, as we can produce a light far brighter than those currently available in the marketplace. LED lights only use 5% of the equivalent energy of incandescent lights, with almost no heat, so developing products utilizing this technology can make major inroads in cutting energy consumption in this country. Our first product will be of the highest quality, and will function as a driveway lamp with mailbox light, address number lights, and an optional motion-activated light with camera-all powered by solar, with no external wiring required. It will offer incredible value for the consumer. We have other more significant products which we are working on, which will be announced in the weeks to come," said Mr. Bushee.

FEATURED COMPANY

PHANTOM FIBER CORPORATION (OTCBB: PHFB)

Detailed Quote: www.otcpicks.com/quotes/PHFB.php

Company Profile: http://www.otcpicks.com/phantom-fiber.htm

Phantom Fiber Corporation is a leading developer of wireless platform software that enables its customers to deliver high-performance applications across global communications networks to mobile users. The company's wireless platform extends the rich multimedia content and user experience of existing Internet web sites securely and instantly to over 1,500 mobile devices including cellular phones and PDAs. This platform is already deployed to most segments of the global gaming industry and can be used by enterprises seeking to implement high performance mobile applications in such markets as: remote video surveillance; banking and brokerage applications; as well as the logistics and distribution markets. Visit www.phantomfiber.com for more information about Phantom Fiber.

PHFB News:

October 30 - Mahjong Time Signs a Multi-Year Contract With Phantom Fiber Corporation to Create a Mobile Extension to Their Leading Online Mahjong Gaming Platform

Mahjong Time, the leading software provider for the online mahjong gaming community, announced a multi-year contract with Phantom Fiber Corporation (OTCBB: PHFB), a leading wireless transaction enablement company specializing in the gaming and entertainment sector. Under the terms of the deal, Phantom Fiber will receive an integration fee and will then share in the ongoing revenue generated from the mobile subscribers.

The integration will allow Mahjong Time to continue delivering the functionality, graphics and speed that users have come to expect from their industry leading software platform and internet offering to over 1,000 handset types. In addition to this, the mobile extension will also offer features that have established Mahjongtime.com as the number one online Mahjong community; these features include multiple game types, multiple languages, practice play, and tournament play. The mobile product will operate on hundreds of device types including Java phones, Apple iPhone, Blackberry, Palm, Microsoft Pocket/PC and Smartphone based handheld devices from anywhere in the world.

"We are quickly being recognized as the dominant mahjong provider in the online arena and we have a strong brand in the Asian market, but I think we all realize that the Asian market is a very mobile and technical savvy geographic area," said William Sutjiadi, CEO of Mahjong Time. "We knew it was a matter of time before we would have to provide a mobile solution. Choosing Phantom Fiber was easy. Their ability to provide the only mobile solution that works globally, their unprecedented support for handsets, and most of all their experience in mobile multi-user environments will ensure the success of this project."

Jeff Halloran, Chairman & CEO of Phantom Fiber, stated, "This agreement has a number of benefits for Phantom Fiber. We recognize the magnitude of the Asian market and their passion for Mahjong. Extending the premier Mahjong platform to a mobile environment will extend Phantom Fiber's reach into those markets. Our multi-user experience from the gaming space and our ability to support multiple languages also blends nicely with our technology. We have been talking with Mahjong Time for some time and have watched them grow in popularity and have some great successes. We are glad the time is right to work with Mahjong Time and share in those successes."

The solution will provide the game content in a number of formats. The player can play against the computer or fully interact with the online community. By using the same login credentials as the internet, a player can search for friends who may be playing online via the internet and join the same games and contests as any other internet player, only from their mobile device.

ABOUT MAHJONG TIME

Founded in 2004, Mahjong Time is a San Diego-based company that is the premier provider of mahjong software and complete turnkey solutions. The Mahjong Time in-browser platform is available in seven languages and provides multiple mahjong rules sets that appeal to the needs of discerning players worldwide. Offered features include advanced subscription and tournament play, and Web 2.0 capabilities that allow players greater connectivity including the ability to establish multiple "friend" networks and to create private game rooms.

Mahjong Time is the exclusive online tournament partner of the annual World Series of Mahjong. The company is also involved in a strategic partnership with Cryptologic, the leading public developer and supplier of Internet gaming software. For more information, visit www.mahjongtime.com.

FEATURED COMPANY

GREENCHEK TECHNOLOGY INCORPORATED (OTCBB: GCHK)
"Up 19.70% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/GCHK.php

Company Profile:
http://www.otcpicks.com/greenchek-technology/greenchek-technology.htm

GreenChek Technology, Inc. manufactures and distributes hydrogen injection technology devices that primarily focus on mobile transportation applications and industrial generative power applications. It also provides mobile greenhouse gas emissions reduction technology. The company's Onboard Hydrogen Generation and Injection technology is used for emissions reduction technology and fuel economy enhancement in trucks, locomotives, and automobile engines. It has operations in the United States, Canada, Asia, and Europe. The company, formerly known as Ridgestone Resources, Inc., was founded in 2006 and is headquartered in San Francisco, California.

GCHK News:

October 14 - GreenChek Announces a More Aggressive Strategic Plan Following 3rd Party Certification Results

GreenChek Technology Inc. (OTCBB: GCHK), a leading globally focused provider of hydrogen based technology for mobile transportation and stationary power generation applications, reported that they are fast-tracking their Strategic Sales Plan as a result of the certification process which confirmed prior results of in-house testing. Management is currently targeting Chinese and Canadian companies for rapid deployment of our products.

GreenChek manufactures an emission reducing device simply known as the ERD 1.0, which can be retrofitted to any vehicle or combustible engine regardless of fuel source. This device reduces vehicle emissions as well as increases fuel economy.

GreenChek’s Chief strategy Officer, Donald Walling who was involved directly in the certification process pointed out that, “The validation of our ERD 1.0 with our successful 3rd Party certification from a world recognized company such as Clean Air Technologies Inc., has reaffirmed the significance of our technology.” Walling further noted, “This has given our senior management team even more confidence for us to more aggressively forge forward with our Strategic Plan as well as in building our strategic alliances and plans for Europe.”

GreenChek’s President and CEO Lincoln Park added, “Initially our plan called for GreenChek to make aggressive inroads into Europe and the United States in Q4 2008 through to Q2 2009. We had originally planned to enter the markets in China and Canada late 2009 and into 2010. However, since our 3rd Party Certification we are now more optimistic and are currently entertaining discussions with various Chinese companies in addition to mapping out our approach to attack and penetrate the Canadian market as well.”

FEATURED COMPANY

PERF GO GREEN HOLDINGS INCORPORATED (OTCBB: PGOG)
"Up 7.69% in morning trading"

Detailed Quote: www.otcpicks.com/quotes/PGOG.php

Company Profile:
http://www.otcpicks.com/perf-go-green/perf-go-green.htm

Perf Go Green Holdings, Inc. is engaged in the creation and global marketing of 100% eco-friendly, non-toxic, food-contact-compliant, biodegradable plastic products. All Perf Go Green products are made from recycled plastics and completely break down in landfill within two years, leaving no toxic or visible residue, as compared to other plastics that take hundreds of years. Perf Go Green’s corporate name reflects its “Go Green” mission to develop, market and distribute biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment.

PGOG News:

October 28 - Perf Go Green Adds Leading Supermarket Chain Hy-Vee, Inc. to Distribution Network

Perf Go Green Holdings, Inc. (OTCBB: PGOG) (“Perf Go Green”), a marketer and distributor of biodegradable plastics, announced a distribution agreement with Hy-Vee, Inc. One of the top 30 supermarket chains in the U.S., Hy-Vee operates more than 224 retail stores in the Midwest.

“Our agreement with Hy-Vee is another sign of the overwhelmingly enthusiastic reception retailers are giving our biodegradable plastic bags,” said Perf Go Green Chairman and CEO Tony Tracy. “We're especially excited about this new partnership because Hy-Vee is well-known for its commitment to sustainability and its leadership in bringing health and wellness to mainstream consumers. Perf Go Green's earth-friendly products offer a meaningful way for consumers, companies and their employees to reduce their environmental footprint.”

Perf Go Green will begin shipping its 13-gallon kitchen trash bags and its 30-gallon lawn and leaf bags to Hy-Vee in November 2008.

Founded in 1930, Hy-Vee, Inc. is an employee-owned corporation operating more than 224 retail stores in seven Midwestern states. For 2007 the company recorded total sales of $5.6 billion, ranking it among the top 30 supermarket chains and the top 50 private companies in the U.S.

Founded in November 2007, Perf Go Green premiered at the March 2008 International Home and Housewares Show in Chicago, where its products received an honor for their design quality and innovation. Perf Go Green is proud to be part of the nation's “go green” movement, which is poised to become a $500 billion market by 2009, according to Landor Associates.

Perf Go Green products incorporate recycled plastics that are combined with an Oxo-Biodegradable proprietary application method to produce the film for its bags. Based on environmental claims statements made by the manufacturer of the Oxo-Biodegradable applied to our bags, when discarded in soil and exposed to the presence of microorganisms, moisture and oxygen, we believe Perf Go Green products biodegrade within two years, decomposing into simple materials found in nature much faster than regular plastics, which can take hundreds of years to break down. Through this process and the use of recycled plastics, Perf Go Green effectively removes plastic waste from the environment. In addition, Perf Go Green trash bags utilize a unique patented dispensing system that stores the bags on the bottom of trashcans and dispenses them one at a time, similar to a tissue box.

FEATURED COMPANY

MEDIVISOR INCORPORATED (OTC: MVSR)

Detailed Quote: www.otcpicks.com/quotes/MVSR.php

Company Profile: http://www.otcpicks.com/medivisor/medivisor.htm

Medivisor, Inc. provides medical information to healthcare professionals, primarily physicians, through its Web sites, using inter-active, informational, and video and graphic presentations. It also focuses on offering Web site services to various industries seeking direct access to physicians, including providers of continuing medical education courses; sponsors of medical conferences and seminars; and pharmaceutical companies, using an online marketing format known as e-detailing. The company was founded in 2002 and is headquartered in Huntington Station, New York.

MVSR News:

October 15 - Medivisor, Inc. Signs Additional Agreement for Distribution of 'Maximum Energy Shot'; Terms Include $500,000 Minimum Orders for Renewable Contract

Medivisor, Inc. (OTC: MVSR), developer of next-generation focus driven marketing tools, announced today that it has entered into an agreement with Stack-It Distributors, Inc. for the distribution of its newly announced energy drink, Maximum Energy Shot. Medivisor has retained Stack-It Distributors, Inc. to distribute its energy drink, and Stack-It Distributors Inc. is to provide minimum orders of $500,000 for an annually renewable contract. The agreement with Stack-It Distributors is substantially similar to Medivisor's previously announced agreement with Market Quest USA.

"Industry dynamics are changing at a rapid pace and the opportunity to enter into the fastest growing segment of the beverage industry, energy drinks, along side of Medivisor, Inc. is a great opportunity," stated Stack-It President Robert Kaible. "We share common vision and values and expect the brand, Maximum Energy Shot, to be a sales success."

Stack-It Distributors, Inc. is a full-service distribution company committed to being the beverage distributor of choice in the Northeast, sustaining profitable growth for the brands it represents. Headquartered on Long Island, NY, Stack-It prides itself on providing remarkable service to its customers and providing a great culture for its teammates.

STOCKS TO WATCH

DATATRAK INTERNATIONAL INCORPORATED (NASDAQ: DATA)
"Up 72.73% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DATA.php

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the United States Food and Drug Administration (FDA), faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the FDA or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio and Bryan, Texas.

DATA News:

October 30 - DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008

DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, announced that it will host a conference call to discuss third quarter and nine month operating results for 2008 at 4:30 p.m. ET on Thursday, November 6, 2008.

To participate via phone, participants are asked to dial 412-858-4600 a few minutes before 4:30 p.m. ET. The conference call will also be available via live web cast on DATATRAK International, Inc.'s web site by clicking the button labeled "Click here for Live Web Cast, 3rd Quarter Earnings Call" on the Company's homepage at www.datatrak.net a few minutes before 4:30 p.m. ET.

A replay of the phone call and web cast will each be available at approximately 6:30 p.m. ET on November 6, 2008 and will run until 9:00 a.m. ET on November 13, 2008. The phone replay can be accessed by dialing 412-317-0088 (access code 424446). To access the web cast replay go to the Company's homepage at www.datatrak.net and click the button labeled "Click here for Replay of Web Cast, 3rd Quarter Earnings Call."

STEMCELLS INCORPORATED (NASDAQ: STEM)
"Up 51.40% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/STEM.php

StemCells, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. The Company’s product development programs seek to repair or repopulate CNS and liver tissue that has been damaged or lost as a result of disease or injury. StemCells has pioneered the discovery and development of HuCNS-SC® cells, its highly purified, expandable population of human neural stem cells. StemCells has completed enrollment and dosing of a six patient Phase I clinical trial of its proprietary HuCNS-SC product candidate as a treatment for neuronal ceroid lipofuscinosis (NCL) and expects the trial to be completed in January 2009. NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative disease that affects infants and young children. StemCells owns or has exclusive rights to more than 50 issued or allowed U.S. patents and more than 150 granted or allowed non-U.S. patents.

STEM News:

October 30 - StemCells, Inc. Announces Preclinical Results Showing its Proprietary Human Neural Stem Cells Can Prevent Vision Loss

StemCells, Inc. (Nasdaq: STEM) reported that its proprietary HuCNS-SC® product candidate (purified human neural stem cells), when transplanted into a well-established animal model, can protect the retina from progressive degeneration. Retinal degeneration leads to loss of vision in diseases such as age-related macular degeneration and retinitis pigmentosa. This promising study was conducted by Dr. Raymond Lund, a researcher and professor at the Casey Eye Institute at Oregon Health & Science University (OHSU) and his research team. Dr. Lund will present the study results at a seminar sponsored by the Foundation Fighting Blindness on Saturday, November 1, 2008. The seminar is scheduled to begin at 9:00 a.m. and will be held at the University of California – San Francisco, Cole Hall (Medical Sciences Building on Parnassus Campus) in San Francisco, California.

“This study confirms the results of previously published academic studies evaluating neural stem cell transplantation into the retina and provides us with the rationale to pursue clinical testing of HuCNS-SC cells for retinal disorders,” said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. “We are already conducting additional preclinical studies and a pre-IND meeting has been scheduled with the FDA for December of this year to determine the pathway to a successful IND filing.”

In this preclinical study, Dr. Lund and his co-investigator at OHSU, Dr. Peter Francis, transplanted HuCNS-SC cells into the Royal College of Surgeons (RCS) rat, a well established animal model of retinal degeneration. In the RCS model, a genetic mutation causes dysfunction of the retinal pigmented cells. Dysfunction in these cells, whose normal function is to support photoreceptors in the eye, causes progressive loss of the photoreceptors and degeneration of the retina, and ultimately, loss of visual function. Photoreceptor loss in the RCS rat begins as early as three weeks of age and by 24 weeks all photoreceptors are typically lost. In the study, the researchers transplanted HuCNS-SC cells into one eye of 21-day-old RCS rats while keeping the opposite eye as the control. Animals were evaluated starting at day 40 (19 days post transplant) and then at routine intervals up to 150 days post transplant. The evaluations showed that the HuCNS-SC cells survived the transplants and engrafted, and the eyes transplanted with the cells showed preservation of the photoreceptors and stabilization of visual function.

“The HuCNS-SC cell has proven to have very robust survival, preserving vision in our rat model at time points beyond six months,” commented Dr. Lund. “These data are very encouraging and suggest cell-based therapies for retinal degeneration can be a viable treatment approach.”

Dr. Francis, a retina specialist and researcher, added, “I am excited by our burgeoning collaboration with StemCells. The results of the early preclinical studies support the potential for these cells to treat retinal degenerative disease. I am especially excited by the fact that the cell is currently being tested in a clinical trial for Batten disease, a disorder of the central nervous system, which should make the transition from the laboratory to clinical use in retinal disease that much easier.”

Dr. Lund received his PhD in Anatomy from University College London, after which he joined the faculty and received tenure within two years. Shortly thereafter, he moved to the United States, joining the faculty at Stanford University. Throughout his career, Dr. Lund has held several impressive academic positions including Chair of the Anatomy Department at the Medical University of South Carolina, Chair of the Neurobiology and Anatomy Department at the University of Pittsburgh, chair of the Anatomy Department at the University of Cambridge in England, the Duke Elder Professorship at the Institute of Ophthalmology in London, and the Calvin and JeNeal Hatch Chair of Ophthalmology at the Moran Eye Center at the University of Utah. In 2005, he was appointed Vice Chair of research at the Moran Eye Center in Utah. In 2007, Dr. Lund was recruited to join the faculty of the Oregon Retinal Degeneration Center at the Casey Eye Institute.

Throughout his career, Dr. Lund’s research has centered on the response of the central nervous system to injury and mechanisms of rescue and repair. Focusing on the retina and its connections with the brain, he pioneered eye transplants in mammals in the late 1970s. Currently, he is investigating the use of cell-based therapies for photoreceptor degeneration in animal models of human disease.

Dr. Francis is an ophthalmologist and retina specialist at the Casey Eye Institute, and an Associate Professor, Oregon Health & Science University. Dr. Francis received his MD from University of Southampton, Southampton, England, and his PhD in molecular genetics at the Institute of Ophthalmology in London. He co-directs the Casey Macular Degeneration and Oregon Retinal Degeneration Centers. His clinical and research interests have focused on age-related macular degeneration and inherited retinal disorders.

ABOUT RETINAL DEGENERATION

The retina is a thin layer of neural cells that lines the back of the eye and is responsible for converting external light into neural signal processed by the brain. The loss of function in retinal cells leads to an impairment or loss of vision. The macula, one of the most critical parts of the retina, is responsible for processing detailed vision. The most common forms of retinal degeneration are age-related macular degeneration and retinitis pigmentosa. In the United States, age-related macular degeneration affects over 1.7 million people in the over-65 population and is the leading cause of blindness in that group. Retinitis pigmentosa is a class of hereditary diseases that also leads to progressive degeneration of retinal cells. In the United States, the most common types of retinitis pigmentosa affect approximately 65,000 people. Preventative measures for both age-related macular degeneration and retinitis pigmentosa have limited impact on the disease and current treatments are not curative.

ABOUT HUCNS-SC CELLS

StemCells’ lead product candidate, HuCNS-SC cells, is a purified composition of normal human neural stem cells that are expanded and stored as banks of cells. The Company’s preclinical research has shown that HuCNS-SC cells can be directly transplanted; they engraft, migrate, differentiate into neurons and glial cells; and they survive for as long as one year with no sign of tumor formation or adverse effects. These findings show that HuCNS-SC cells, when transplanted, act like normal stem cells, suggesting the possibility of a continual replenishment of normal human neural cells.

ABOUT OHSU AND CASEY EYE INSTITUTE

Oregon Health & Science University is Oregon’s only health and research university and the state’s only academic health center. OHSU is Portland’s largest employer and the fourth largest in Oregon (excluding government), with more than 12,400 employees. OHSU’s size contributes to its ability to provide many services and community support activities not found anywhere else in the state. It serves patients from every corner of the state, and is a conduit for learning for more than 3,400 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to every county in the state.

The Casey Eye Institute, named after the founders of United Parcel Service, opened on the OHSU Marquam Hill Campus in 1991. The Casey Eye Institute is an academic regional eye center dedicated to preventing blindness through research, and to bringing advanced technology to the Pacific Northwest through continuing education of physicians. Casey is the seventh and final regional eye research center in the nation sponsored by Research to Prevent Blindness, the world's leading voluntary organization in support of eye research.

ADVANCED CELL TECHNOLOGY INCORPORATED (OTC: ACTC)
"Up 50.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ACTC.php

Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. It primarily focuses on cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company also develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. It also plans to develop and commercialize products for use in the treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, infarction, and burns. The company has research and license agreements with University of Massachusetts, Wake Forest University, WiCell Research Institute, Inc., Kirin Beer Kabushiki Kaisha, and Start Licensing. Advanced Cell Technology, Inc. is headquartered in Worcester, Massachusetts.

ACTC News:

October 30 - Advanced Cell Technology, Inc. Increases Funding Commitment to $1 Million

Advanced Cell Technology, Inc. (OTC: ACTC) announced today that an Irish institutional investor has increased its funding commitment to the Company by $500,000. Transition Holdings, Inc, which has already provided an additional $150,000 in funding, has increased its total commitment under which it will purchase a total of $1 million of one-year 7% convertible debentures over the next six months. The Company will use the proceeds for working capital, general corporate purposes and to continue the development of its most advanced clinical programs. The Company continues to negotiate with partners to jointly develop its pre-clinical and certain clinical programs in heart failure, retinal disease and the production of red blood cells.

“We are pleased that there are still investors who recognize the opportunities for our technology platform and the prospects to develop it through a more supportive political environment for stem cell companies as a result of the upcoming change in the administration,” said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc. “At a time where a lack of funding in the capital markets has created unprecedented challenges for development-stage biotechnology companies, Advanced Cell has managed to raise enough capital to continue operations, although on a far more limited basis than is desirable. Despite these funding difficulties, the Company has reduced debt from an aggregate balance of $49 million to a face value of $13 million over the past three years. We look forward to the upcoming Presidential Election and renewed governmental support for the stem cell industry.”

FRANKLIN BANK CORPORATION (NASDAQ: FBTX)
"Up 82.29% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/FBTX.php

Franklin, headquartered in Houston, Texas, was formed in April 2002. Franklin's common stock initiated trading on the Nasdaq Stock Market in December 2003 under the ticker symbol "FBTX." In May 2006, Franklin raised additional capital through an offering of its Series A Non-Cumulative Perpetual Preferred Stock that is now trading on The American Stock Exchange under the ticker symbol "FBK-P." Through the Bank, Franklin offers a wide variety of consumer and business products and services. The Bank focuses on providing high-quality personalized service through its trusted financial advisors and strives to meet all of the financial needs of its customers. In addition to various deposit and loan products, the Bank offers retail brokerage services through a third-party provider.

FBTX News:

November 2 - Franklin Bank Corp. Receives Non-Binding Proposals for the Recapitalization of Franklin Bank, S.S.B. Franklin Bank, S.S.B. Submits Call Report for Third Quarter 2008

Franklin Bank Corp. (Nasdaq: FBTX) (AMEX: FBK-P) (“Franklin”) announced today that it has received proposals regarding transactions that would strengthen the capital position of its subsidiary Franklin Bank, S.S.B. (“Bank”). Franklin is engaged in discussions with these parties about the terms and timing of any such transaction, and is keeping regulatory authorities informed of the progress of the discussions. Consummation of any one of the proposals would restore the Bank's capital category, for regulatory purposes, to the well-capitalized category.

The proposals are non-binding, subject to satisfactory completion of due diligence, approval of the final terms by the relevant boards of directors, execution of definitive agreements, receipt of certain approvals of or waivers by applicable regulatory authorities and other conditions customary in such transactions. It is expected that consummation of any transaction, which would be expected by year-end, also will require the approval of Franklin's stockholders. No assurance may be given that any agreement will be concluded or any transaction consummated.

“The challenges in the financial services industry we are facing today are without precedent,” said Alan Master, CEO and President of Franklin. “Our announcement today is intended to inform stakeholders in Franklin that the board continues to seek the best opportunity for the Bank to meet and solve these challenges.”

Call Report

The Bank is required to submit to the Federal Deposit Insurance Corporation (the “FDIC”), on a quarterly basis, its Consolidated Reports of Condition and Income, referred to herein as “call reports.” The Bank's call reports are prepared in accordance with instructions issued by the Federal Financial Institutions Examination Council and include a balance sheet, income statement, changes in equity capital and other supporting schedules as of the end of the period covered by each call report. The publicly available portions of the Bank's call reports are available on the FDIC's website at www4.fdic.gov/call_tfr_rpts.

On October 30, 2008, the Bank submitted to the FDIC a call report as of and for the nine months ended September 30, 2008 (the “September Call Report”). The September Call Report indicates that, as of September 30, 2008, the Bank's capital category for purposes of the prompt corrective action provisions of Section 38 of the Federal Deposit Insurance Act is significantly undercapitalized. Additionally, the Bank intends to submit to the FDIC an amended call report as of and for the six months ended June 30, 2008, which is expected to show that as of that date the Bank's capital category was significantly undercapitalized. The transactions contemplated by the proposals currently under discussion will return the Bank to the well capitalized category and provide additional excess capital.

The financial results reported in the Bank's call reports submitted to the FDIC reflect the operations of the Bank only, and do not include holding company operations of Franklin. In addition, financial information contained in the Bank's call reports is unaudited and has not been reviewed by Franklin's independent accountants. As previously reported, Franklin's filing of its annual report on Form 10-K, including its audited financial statements, for the year ended December 31, 2007 has been delayed. While the September Call Report reflects the best information available as of the time of its submission, the information in the September Call Report is subject to possible revision in connection with the audit of Franklin's financial statements since the books and records of Franklin for 2007 have not yet been closed. Accordingly, the information contained in the September Call Report is subject to these and the other qualifications contained in this press release.

OPEXA THERAPEUTICS INCORPORATED (NASDAQ: OPXA)
"Up 34.95% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/OPXA.php

Opexa Therapeutics, Inc. a development stage biopharmaceutical company, develops autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, and diabetics. Its therapies are based on the company's T-cell and adult stem cell technologies. The company's products include Tovaxin, a T-cell therapeutic vaccine that is in Phase IIb clinical trial for the treatment of multiple sclerosis. Its Rheumatoid Arthritis T-cell vaccination technology, which is in preclinical development stage allows the isolation of pathogenic T-cells from synovial fluid drawn from a patient; as well as Adult Stem Cell technology that is in preclinical development stage is used to treat diabetes; and is in research and development stage to treat heart failure. The company was founded in 2003. It was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in 2006. Opexa Therapeutics is based in the Woodlands, Texas.

OPXA News:

October 23 - Opexa Therapeutics Reports Third Quarter 2008 Financial Results

Opexa Therapeutics, Inc. (Nasdaq: OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, reported financial results for the quarter ended September 30, 2008, and provided an update on its recent accomplishments. Recent Highlights:

* Completed first-in-class Phase IIb TERMS (Tovaxin® for Early Relapsing Multiple Sclerosis) clinical study evaluating Tovaxin, a novel patient-specific treatment for MS. Top-line findings, which were reported in September 2008 at the World Congress on Treatment and Research in Multiple Sclerosis include:

* Annualized relapse rate (ARR) of 0.214 for patients treated with Tovaxin, which compares favorably to the lowest ARRs reported in studies of any MS therapy on the market or in development.

* Excellent safety with no serious adverse events attributed to Tovaxin.

* Additional data analysis, which focused on patients with the most active disease (prospectively defined ARR>1 population) provided the following findings:

* Tovaxin-treated patients experienced a statistically significant improvement in disability as measured by the Expanded Disability Status Scale (EDSS) (p=0.045) as compared to placebo.

* Tovaxin-treated patients experienced an improvement in brain atrophy and in the number of Gadolinium enhanced (Gd) lesions as well as in T-2 lesion volumes, as compared to patients receiving placebo.

* Tovaxin-treated patients had less T-cell reactivity and experienced fewer relapses as compared to patients on placebo suggesting that Tovaxin may lower the risk of relapse for patients in this population.

* Completed enrollment of one-year open label extension study of Tovaxin. Approximately 90 percent of patients in the Phase IIb TERMS study elected to participate.

* Completed a private placement financing with gross proceeds of approximately $3 million.

“Opexa’s Phase IIb TERMS study provided important data which highlighted Tovaxin’s potential therapeutic benefit to those patients suffering with more active disease and most in need of treatment,” commented Neil K. Warma, president and chief executive officer of Opexa. “Earlier today, we were pleased to report Tovaxin’s positive results with the prospectively defined ARR>1 population as evidenced by a statistically significant reduction in disability, improvements with respect to brain atrophy and lesions, and an important reduction in T-cell reactivity. Previously, we reported that Tovaxin demonstrated a reduction in ARR to levels on par with the most efficacious currently available MS treatments, as well as an impressive safety and tolerability profile. We are aggressively pursuing the ongoing interest of potential strategic partners to further advance this innovative therapy.”

Third Quarter Financial Results

Opexa recorded no revenues for the three months ended September 30, 2008 or in the comparable prior-year period.

Research and development expenses were approximately $2.4 million for the three months ended September 30, 2008, compared to approximately $3.2 million for the three months ended September 30, 2007. The decrease in expenses was primarily due to a wind down of costs of conducting the Phase IIb clinical trial for Tovaxin recorded in 2008 offset in part by costs associated with enrollment of the one-year Phase IIb extension study of Tovaxin.

General and administrative expenses were approximately $0.7 million for the three months ended September 30, 2008, as compared to approximately $0.8 million for the three months ended September 30, 2007. The decrease in expenses is primarily due to a decrease in stock compensation expense in the current period.

Opexa reported a net loss for the three months ended September 30, 2008, of approximately $3.1 million, or $0.28 per share, compared with a net loss of approximately $2.4 million, or $0.35 per share, for the three months ended September 30, 2007.

The company had cash and cash equivalents of approximately $4.0 million as of September 30, 2008, compared with approximately $2.6 million as of December 31, 2007.

Year-to-Date Financial Results

Opexa reported no revenues in the nine months ended September 30, 2008, or in the comparable prior-year period.

Research and development expenses were approximately $7.1 million for the nine months ended September 30, 2008, compared to approximately $10.1 million for the nine months ended September 30, 2007. The decrease in expenses was primarily due to a decrease in activities related to the Phase IIb clinical trial for Tovaxin in 2008 as compared to 2007 and a reduction in stock compensation expense recorded in 2008.

General and administrative expenses were approximately $2.7 million for the nine months ended September 30, 2008, as compared to approximately $2.6 million for the nine months ended September 30, 2007. The increase in expenses is primarily due to an increase in stock compensation expense during the current period.

Opexa reported a net loss for the nine months ended September 30, 2008, of approximately $9.9 million, or $0.99 per share, compared with a net loss of approximately $10.8 million, or $1.62 per share, for the nine months ended September 30, 2007.

AASTROM BIOSCIENCE INCORPORATED (NASDAQ: ASTM)
"Up 38.80% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ASTM.php

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. Ongoing development activities are focused on applying TRC technology to cardiac and vascular tissue regeneration. The Company is currently focused on cardiovascular regeneration and is conducting a Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI trial).

ASTM News:

October 30 - Aastrom Announces Achievement of Milestone in U.S. Phase IIb Critical Limb Ischemia Clinical Trial

Company to Analyze Interim Data After 30th Patient Completes One Year Follow-Up

Aastrom Biosciences, Inc. (Nasdaq: ASTM), a leading regenerative medicine company, announced that the 30th patient has been treated in the Company's U.S. Phase IIb RESTORE-CLI clinical trial. This milestone marks the first step toward interim data retrieval from this clinical trial evaluating Aastrom's Vascular Repair Cells (VRCs) in the treatment of patients suffering from the most severe form of peripheral arterial disease (PAD), critical limb ischemia (CLI). After the 30th patient has been followed for one year the Company will be able to unblind and analyze the interim data.

The RESTORE-CLI clinical trial is a prospective, controlled, randomized, double-blind, multi-center study that is reviewed quarterly by a sponsor-appointed, independent Data and Safety Monitoring Board (DSMB). The DSMB is composed of third-party experts in vascular surgery, cardiovascular medicine, stem cell research and biostatistics. The DSMB has unblinded access to all available patient data. They review patient safety as well as efficacy information on an ongoing basis. At their September 24, 2008 meeting, the independent DSMB unanimously recommended continuation of the study.

“Treating the 30th patient in the RESTORE-CLI trial is a significant clinical accomplishment for Aastrom as we are now able to target the timing for the next milestone — reporting interim data from this first set of critically ill patients,” said George Dunbar, President and Chief Executive Officer of Aastrom. “These patients face a high risk of major limb amputation and may benefit from Aastrom's VRC treatment.”

Approximately 10 million people in the U.S. suffer from PAD; of this group, 900,000 suffer from the most severe form, CLI, which leads to 100,000 amputations per year. PAD is a chronic disease that progressively restricts blood flow in the limbs and can lead to serious medical complications. This disease is often associated with other clinical conditions, including hypertension, cardiovascular disease, hyperlipidemia, diabetes, obesity and stroke. The term CLI is used to describe patients with chronic ischemia-induced pain (even at rest), ulcers, tissue loss or gangrene in the limbs. CLI represents the end stage for PAD patients.

MEMORY PHARMACEUTICALS CORPORATION (NASDAQ: MEMY)
"Up 28.80% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MEMY.php

Memory Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer's disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression. The company's products include MEM 1003, a neuronal L-type calcium channel modulator that is in phase II clinical trials for the treatment of Alzheimer's disease and bipolar disorder; and nicotinic alpha-7 agonists, including MEM 3454, a phase IIa clinical trial product and MEM 63908, a phase I clinical trial product for the treatment of Alzheimer's disease and CIAS. Its products also comprise PDE4 inhibitors, including MEM 1414, a phase I clinical trial program, as well as MEM 1917 for CNS disorders and depression; PDE10 Inhibitor program; and 5-HT6 Antagonists for the treatment of Alzheimer's disease, schizophrenia, attention deficit disorder, and obesity. The company has collaborations with F. Hoffman-La Roche, Ltd. for the development of nicotinic alpha-7 agonists; and Amgen, Inc. for the development of PDE10 inhibitors. In addition, it has a development agreement with The Stanley Medical Research Institute to develop MEM 1003 as a treatment for bipolar disorder. The company was founded in 1997 and is based in Montvale, New Jersey.

MEMY News:

October 31 - Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements

Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced that the NASDAQ Listing Qualifications Panel has granted the Company's request for an extension until December 3, 2008 to comply with the NASDAQ Capital Market minimum market capitalization requirement of $35 million or the alternative requirement of $2.5 million in stockholders' equity in order to remain listed. There can be no assurance that the Company will achieve compliance by the specified deadline.